CancerDrs

Brain Cancer clinical trials in Arizona

27 actively recruiting brain cancer trials at 5 sites across Arizona.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Arizona:
  • Banner Children's at Desert — Mesa, Arizona
  • Phoenix Childrens Hospital — Phoenix, Arizona
Phase 3 Recruiting Network

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …

Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Arizona:
  • Phoenix Childrens Hospital — Phoenix, Arizona
Phase 3 Recruiting Network

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Sites in Arizona:
  • University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
Phase 3 Recruiting Industry

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation o…

Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT07195591
Sites in Arizona:
  • HonorHealth Scottsdale Osborn Medical Center — Scottsdale, Arizona
Phase 3 Recruiting Industry

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…

Sponsor: InSightec
NCT ID: NCT05317858
Sites in Arizona:
  • St. Joseph's Hospital and Medical Center — Phoenix, Arizona
Phase 3 Recruiting Academic/Other

Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors

This phase III trial studies the side effects and how well stereotactic radiosurgery (SRS) works before or after surgery in patients with tumors that has spread to the brain or that can be removed by surgery. Stereotactic radiosurgery is a…

Sponsor: Mayo Clinic
NCT ID: NCT03750227
Sites in Arizona:
  • Mayo Clinic in Arizona — Scottsdale, Arizona
Phase 2 Recruiting Network

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …

Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Arizona:
  • Banner Children's at Desert — Mesa, Arizona
  • Phoenix Childrens Hospital — Phoenix, Arizona
  • Banner University Medical Center - Tucson — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
Phase 1, Phase 2 Recruiting NIH

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozo…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05432804
Sites in Arizona:
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Phase 1, Phase 2 Recruiting Network

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…

Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Arizona:
  • Phoenix Childrens Hospital — Phoenix, Arizona
Phase 2 Recruiting Academic/Other

Digoxin Medulloblastoma Study

The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.

Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT06701812
Sites in Arizona:
  • Phoenix Childrens Hospital — Phoenix, Arizona
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients

The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with your standard…

Sponsor: Myosin Therapeutics Inc.
NCT ID: NCT07185880
Sites in Arizona:
  • Mayo Clinic Hospital — Phoenix, Arizona
Phase 2 Recruiting Academic/Other

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

This phase II trial tests how well retifanlimab with bevacizumab and hypofractionated radiotherapy, compared to bevacizumab and hypofractionated radiotherapy alone, works in treating patients with glioblastoma that has come back after a pe…

Sponsor: Academic and Community Cancer Research United
NCT ID: NCT06160206
Sites in Arizona:
  • Mayo Clinic in Arizona — Scottsdale, Arizona
Phase 1, Phase 2 Recruiting Academic/Other

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 pat…

Sponsor: University of Arizona
NCT ID: NCT06814496
Sites in Arizona:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
  • Arizona Cancer Center at UMC North/University Medical Center — Tucson, Arizona
EARLY Phase 1 Recruiting Academic/Other

Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis

The goal of this diagnostic intervention clinical trial is to compare 18F-Fluciclovine uptake within brain lesions over 60 minutes compared with standard of care positive histology confirmation or confirmation MRI images. The main question…

Sponsor: University of Arizona
NCT ID: NCT06055790
Sites in Arizona:
  • Arizona Cancer Center at UMC North/University Medical Center — Tucson, Arizona
EARLY Phase 1 Recruiting Academic/Other

BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors

This is an open-label, multi-center, Phase 0/2 trial designed to enroll up to 78 total participants with suspected newly diagnosed glioblastoma (nGBM) who are scheduled for surgical resection to accrue at least 14 participants in Arm A and…

Sponsor: Nader Sanai
NCT ID: NCT07485049
Sites in Arizona:
  • St. Joseph's Hospital and Medical Center — Phoenix, Arizona
EARLY Phase 1 Recruiting Academic/Other

Clinical Trial of BMS-986504 in Recurrent GBM Patients

This is an open-label, multi-center, Phase 0/1 dose-escalation trial designed to enroll up to 12 total recurrent glioblastoma (rGBM) participants with confirmed MTAP loss/deletion in their archival or pretreatment biopsy tissue, who are sc…

Sponsor: Nader Sanai
NCT ID: NCT06883747
Sites in Arizona:
  • St. Joseph's Hospital and Medical Center — Phoenix, Arizona
EARLY Phase 1 Recruiting Academic/Other

A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

This will be an open-label Phase 0/1 study that will enroll approximately 15 participants, 9 participants with recurrent WHO Grade 4 glioma (rGBM) and 6 participants with brain metastases, who will receive the investigational drug risvutat…

Sponsor: Nader Sanai
NCT ID: NCT07268053
Sites in Arizona:
  • St. Joseph's Hospital and Medical Center — Phoenix, Arizona
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Arizona:
  • Massive Bio SYNERGY-AI site — Scottsdale, Arizona
Phase 4 Recruiting Industry

Dabrafenib and/or Trametinib Rollover Study

This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the r…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT03340506
Sites in Arizona:
  • Honor Health Research Institute — Scottsdale, Arizona
NA Recruiting Academic/Other

Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma

This clinical trial studies whether continuous glucose monitoring (CGM) can be used to help patients with glioblastoma manage their blood sugar (glucose) levels and improve survival. Glioblastoma is the most common malignant primary brain …

Sponsor: Mayo Clinic
NCT ID: NCT07091864
Sites in Arizona:
  • Mayo Clinic in Arizona — Phoenix, Arizona
NA Recruiting Academic/Other

Cancer Genetic Testing in Ethnic Populations

This clinical trial examines the integration of cancer genetic testing in various ethnic populations. Studying individuals and families at risk of cancer may help identify cancer genes and other persons at risk. The information from this s…

Sponsor: Mayo Clinic
NCT ID: NCT04475640
Sites in Arizona:
  • Mayo Clinic in Arizona — Scottsdale, Arizona
NA Recruiting Academic/Other

Nasal Outcomes Using Saline Irrigations After Endonasal Pituitary Surgery

This is a prospective, single-blinded, multicenter study evaluating the benefit of sinonasal irrigations following endoscopic pituitary surgery. The goal of this study is to create practice changing guidelines with objective data highlight…

Sponsor: Lori Wood
NCT ID: NCT05659524
Sites in Arizona:
  • Barrow Neurological Institute at St. Joseph's Hospital and Medical Center — Phoenix, Arizona

Showing 25 of 27 trials with sites in Arizona. See all brain cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12